Last reviewed · How we verify
Glibenclamide and Metformin
Glibenclamide stimulates insulin secretion from pancreatic beta cells, while metformin reduces hepatic glucose production and improves insulin sensitivity.
Glibenclamide stimulates insulin secretion from pancreatic beta cells, while metformin reduces hepatic glucose production and improves insulin sensitivity. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Glibenclamide and Metformin |
|---|---|
| Also known as | Diabeta, Glynase, Micronase, Daonil, Semi-Daonil |
| Sponsor | Takeda |
| Drug class | Sulfonylurea + Biguanide combination |
| Target | ATP-sensitive potassium channel (Kir6.2/SUR1); AMPK and mitochondrial complex I |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Glibenclamide is a sulfonylurea that closes ATP-sensitive potassium channels on beta cells, triggering insulin release. Metformin is a biguanide that decreases gluconeogenesis and glycogenolysis in the liver and enhances peripheral glucose uptake and utilization. Together, they provide complementary mechanisms to lower blood glucose in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)
- Weight gain
- Lactic acidosis (rare)
- Headache
Key clinical trials
- Diabetes Management for Primary Healthcare Centers. (NA)
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Investigation of the Efficacy of Metformin Therapy on Pulmonary Sarcoidosis (PHASE2)
- Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus (PHASE4)
- Comparison Between Metformin and Glyburide in the Management of Gestational Diabetes (NA)
- Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM (PHASE4)
- Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.
- Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fed (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glibenclamide and Metformin CI brief — competitive landscape report
- Glibenclamide and Metformin updates RSS · CI watch RSS
- Takeda portfolio CI